Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Recent papers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center

1. Targeted Sequencing Yields High Rate of Pathogenic Variants in Both Single and Multilineage Pediatric Immune CytopeniasAmerican Journal of Hematology · 2026
2. Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology GroupJournal of Clinical Oncology · 2026
3. Iterative computational and rational design generates diverse PET hydrolases for plastic depolymerizationNature Communications · 2026
4. “Food is like all we do all day”: a qualitative exploration of nutritional challenges and intervention needs among families of early childhood cancer survivorsSupportive Care in Cancer · 2026
5. Standard treatment against paediatric BRAF-V600E glioma promotes senescence and sensitizes tumours to BCL-xL inhibitionNeuro-Oncology · 2026
6. Circulating Biomarkers of Disease Burden in Patients With Relapsed or Refractory Neuroblastoma Treated With 131 I‐MIBG Therapy: A Report From the New Approaches to Neuroblastoma Therapy ConsortiumPediatric Blood & Cancer · 2026
7. Current State of Allogeneic Hematopoietic Cell Transplantation for Still's Disease: A Collaborative Perspective from Attendees of the Systemic Juvenile Idiopathic Arthritis Foundation NextGen ConferenceArthritis Care & Research · 2026
8. Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumJNCI Journal of the National Cancer Institute · 2026
9. Neutrophil extracellular traps and DNase I levels in the bronchoalveolar lavage fluid of children with pulmonary injury after allogeneic hematopoietic stem cell transplantation: a TRANSPIRE studyHaematologica · 2026
10. Safety and Efficacy of Photon Re-Irradiation with Whole-Brain Radiotherapy or Craniospinal Irradiation for Recurrent Pediatric Central Nervous System MalignanciesCurrent Oncology · 2026
11. Selpercatinib in Pediatric and Adolescent Patients With RET -Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 StudyJournal of Clinical Oncology · 2026
12. A phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M)The Oncologist · 2026
13. The Impact of Older Age at Diagnosis on Wilms Tumor Characteristics and Patient Outcomes: A Children’s Oncology Group StudyJournal of the National Comprehensive Cancer Network · 2026
14. Impact of Extent of Surgical Resection on Survival in Patients With High-risk NeuroblastomaAnnals of Surgery · 2026
15. Immunotherapy-Based Therapies in Pediatric Hodgkin Lymphoma: Potential to Narrow the Gap in Long-Term SurvivalJNCI Journal of the National Cancer Institute · 2026
16. Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell diseaseCell stem cell · 2026
17. Ras-MAPK somatic variants in mesial temporal lobe epilepsyCurrent Opinion in Genetics & Development · 2026
18. Impact of Radiation Therapy on Physical and Psychosocial Health of Adolescents and Young Adults: A Joint Report From the Children's Oncology Group AYA and Radiation Oncology CommitteesPediatric Blood & Cancer · 2026
19. Impact of post‐chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children’s Oncology Group AREN0532, AREN0533, and AREN03B2 studiesCancer · 2026
20. Unbiased, systematic surfaceome profiling of Acute Leukemia to identify novel immunotherapy targets2026